Clinical-stage biopharmaceutical company BioAge Labs, Inc. (NASDAQ: BIOA) on Tuesday announced the pricing of its upsized public offering, raising approximately $115 million in gross proceeds. The company said the offering was increased in size following strong demand from investors.
Under the terms of the offering, BioAge priced approximately 5.9 million shares of its common stock at $19.50 per share. The transaction is expected to close on or around January 23, 2026, subject to customary closing conditions.
Offering Structure and Underwriters
BioAge Labs also granted the underwriters a 30-day option to purchase additional shares to cover over-allotments, if any.
The public offering is being led by major global investment banks:
- Goldman Sachs
- Piper Sandler
- Citigroup
These institutions are acting as joint book-running managers for the transaction.
Why the Offering Was Upsized
The company described the offering as “upsized,” meaning it was increased from its originally planned size due to strong investor interest. Upsizing typically reflects confidence from the market in a company’s long-term strategy and growth potential.
For BioAge, the successful pricing suggests continued support from institutional investors despite recent volatility in the biotechnology sector.
Use of Proceeds
BioAge Labs said the net proceeds from the offering will be used for multiple strategic purposes, including:
- Advancing research and development (R&D) programs
- Funding ongoing and upcoming clinical trials
- Supporting manufacturing and technology development
- Strengthening working capital and general corporate operations
The company emphasized that additional capital will help accelerate the development of its aging-focused drug pipeline.
About BioAge Labs
Founded to explore the biology of human aging, BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapies that target the underlying biological mechanisms of age-related diseases.
Unlike traditional drug companies that treat symptoms, BioAge aims to address the root causes of aging-related conditions, using insights derived from large-scale human data and biological research.
Key Drug Programs in Development
BGE-102 – Lead Clinical Candidate
BioAge’s lead drug candidate, BGE-102, targets inflammation pathways associated with aging. The drug is being studied for potential use in:
- Cardiovascular diseases
- Retinal and eye-related disorders
Inflammation is widely believed to play a major role in many age-related illnesses, making BGE-102 a key focus area for the company.
APJ Agonist Program
Another important research area for BioAge is its APJ agonist program, which is aimed at addressing:
- Obesity
- Metabolic disorders
In addition to these programs, the company has several preclinical-stage projects targeting other conditions linked to aging biology.
Company’s Financial and Market Background
BioAge Labs went public in 2024, raising approximately $198 million through its initial public offering. Since then, the company has experienced both progress and challenges, including setbacks in certain clinical programs that led to sharp movements in its share price.
Despite these challenges, BioAge continues to invest heavily in its research pipeline, positioning itself for long-term growth in the emerging longevity and aging therapeutics space.
What This Means for Investors
Industry analysts note that while BioAge operates in a high-risk sector, its scientific focus and ability to raise capital through an upsized offering indicate continued market confidence.
However, as with all clinical-stage biotech companies, BioAge’s future performance will largely depend on:
- Clinical trial results
- Regulatory approvals
- The company’s ability to successfully commercialize its therapies
Investors are expected to closely monitor upcoming trial updates and pipeline developments.
Outcome
The pricing of BioAge Labs’ $115 million upsized public offering marks a significant milestone for the company as it seeks to strengthen its balance sheet and advance its aging-focused drug development efforts. With fresh capital in hand, BioAge aims to accelerate research and move closer to delivering new treatments for age-related diseases.
Market participants will be watching closely to see how the company deploys the funds and progresses through its next phase of clinical development.
Source: Globenewswire , bioagelabs press
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making any financial decisions.
